Sotrovimab

Sotrovimab is a monoclonal antibody drug developed by GlaxoSmithKline and Vir. This drug’s monoclonal antibody (laboratory-bade protein) specifically targets the spike protein of SARS-CoV-2. It is capable of blocking the novel coronavirus’ attachment and entry into the human cells

This monoclonal antibody drug received an emergency use authorisation from the US Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in adults and children above the age of 12. This drug was found to reduce hospitalisation and mortality among coronavirus patients by 85 per cent. Its efficacy was also proven against the new variants of novel coronavirus.